Find the Perfect Plan for Your Investment Journey
A
Latest price
52 Week Range
€4.51 - €15.42
Next Earnings Date
Sep 08 2025 (Estimate)
Next Earnings Date
Sep 08 2025 (Est.)
Latest price
Market Cap | €388.05M |
EV | €352.91M |
Shares Outstanding | 63.41M |
Beta | 1.56 |
Analyst Rating | BUY |
Analyst Target Price | €25.43 |
P/E 2025E | - |
P/Revenue 2025E | 52.88x |
Revenue | 8.80% |
EPS | -4.30% |
Operating Cash Flow | -50.00% |
Free Cash Flow | -48.40% |
Revenue | 81.10% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | -2739.33% |
ROE 2025E | -421.45% |
ROCE 2024 | -148.98% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
A
ABIVAX Société Anonyme
ABVX
Sector
Healthcare
Industry
Biotechnology
CEO
de Garidel, Marc M.
Employees
69
Website
www.abivax.comIPO Date
2015-06-26
Headquarters
7-11 boulevard Haussmann, Paris, Ile-de-France, 75009, France
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved